Cell Therapeutics announces latest trial results for Zevalin

01/22/2009 | RTT News

Patients with mucosa-associated lymphoid tissue lymphoma and low-grade follicular lymphoma in conjunctiva exhibited an 83% complete response rate to Zevalin, Cell Therapeutics' radioimmunotherapy, during a front-line study. The results show that Zevalin could be a good alternative to current treatments, providing lower ocular toxicity and equal or better disease control, said the company's chief medical officer.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC